Abrocitinib, which targets adenosine triphosphate binding sites, was approved by the U.S. FDA in 2022 to treat refractory moderate-to-severe AD and is the first JAK1 inhibitor for AD worldwide. The gene discussed is JAK1; the disease is Alzheimer disease.